<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04653623</url>
  </required_header>
  <id_info>
    <org_study_id>Tranexamic Acid</org_study_id>
    <nct_id>NCT04653623</nct_id>
  </id_info>
  <brief_title>Effect of Tranexamic Acid on Blood Loss After High Tibial Osteotomy</brief_title>
  <official_title>Effect of Tranexamic Acid on Blood Loss After High Tibial Osteotomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Catholic University of Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Catholic University of Korea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to examine whether tranexamic acid has an meaningful clinical effect on blood&#xD;
      loss after high tibial osteotomy. This study design is a double-blind randomized controlled&#xD;
      trial. The patients were randomly assigned to intervention or usual care groups. Intervention&#xD;
      patients receive tranexamic acid 2g for 10 minutes just before surgery. Primary outcome is&#xD;
      hemoglobin level preoperatively, postoperative 1 day, 2 days, 3 days, 2 weeks. Secondary&#xD;
      outcome included hematocrit level, hemovac drainage, total blood loss, need for transfusion,&#xD;
      deep vein thrombosis, Visual Analog Pain Scale, and wound complication.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      High tibial osteotomy is proved treatment option for medial compartment osteoarthritis of&#xD;
      knee joint. Especially, open wedge high tibial osteotomy might cause moderate amount of&#xD;
      bleeding and hematoma formation. Bleeding and hematoma could be a reason of soft tissue&#xD;
      infection and wound complications. Tranexamic acid (TXA) is a medication used to treat or&#xD;
      prevent excessive blood loss from major trauma, postpartum bleeding, surgery, tooth removal,&#xD;
      nosebleeds, and heavy menstruation. The objective of the study is to test whether&#xD;
      preoperative tranexamic acid could reduce the postoperative complications due to bleeding.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemoglobin level</measure>
    <time_frame>Change from Baseline Hemoglbin level at postoperative 1 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemoglobin level</measure>
    <time_frame>Change from Baseline Hemoglbin level at postoperative 2 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemoglobin level</measure>
    <time_frame>Change from Baseline Hemoglbin level at postoperative 3 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemoglobin level</measure>
    <time_frame>Change from Baseline Hemoglbin level at postoperative 2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hematocrit level</measure>
    <time_frame>Preoperative &amp; postoperative 1, 2, 3 days, 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of Hemovac drainage</measure>
    <time_frame>Postoperative 1, 2, 3 days</time_frame>
    <description>CC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total blood loss</measure>
    <time_frame>Postoperative 1, 2, 3 days</time_frame>
    <description>CC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Need for transfusion</measure>
    <time_frame>Postoperative 1, 2, 3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Need for transfusion Deep vein thrombosis</measure>
    <time_frame>Until postoperative 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Pain Scale [0 - 10]</measure>
    <time_frame>Preoperative &amp; postoperative 1, 2, 3 days, 2 weeks</time_frame>
    <description>Higher scores mean worse outcome</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>Tranexamic acid before high tibial osteotomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interventions&#xD;
Procedure/Surgery: High tibial osteotomy&#xD;
Drugs: Tranexamic acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High tibial osteotomy only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Interventions&#xD;
- Procedure/Surgery: High tibial osteotomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>High tibial osteotomy</intervention_name>
    <description>Treatment option for medial compartment osteoarthritis of knee</description>
    <arm_group_label>High tibial osteotomy only</arm_group_label>
    <arm_group_label>Tranexamic acid before high tibial osteotomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic acid</intervention_name>
    <description>Medication used to treat or prevent excessive blood loss from major trauma, postpartum bleeding, surgery, tooth removal, nosebleeds, and heavy menstruation</description>
    <arm_group_label>Tranexamic acid before high tibial osteotomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients for high tibial osteotomy&#xD;
&#xD;
          -  Having medicare insurance&#xD;
&#xD;
          -  Accepted patients&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of lower extremity infection or neurologic problems&#xD;
&#xD;
          -  Inflammatory arthritis&#xD;
&#xD;
          -  Using thrombins&#xD;
&#xD;
          -  History of treatment for anemia&#xD;
&#xD;
          -  History of thromboembolic event&#xD;
&#xD;
          -  Chronic kidney disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Catholic University of Korea Seoul St Mary's hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 20, 2020</study_first_submitted>
  <study_first_submitted_qc>November 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2020</study_first_posted>
  <last_update_submitted>November 30, 2020</last_update_submitted>
  <last_update_submitted_qc>November 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Catholic University of Korea</investigator_affiliation>
    <investigator_full_name>Yong In</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

